← 홈

프로그램 비교

타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일

현재 선택: 1 · 임상 갱신 필요 1

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

API CSV21행 · 1개 프로그램

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
CGTStandard DatabasestalePhase 1
19-28z T CELLS (19-28z T CELLS)
Juno Therapeutics, Inc., a Bristol…·Non-Hodgkin's Lymphoma
11 trials
Overview
Program
19-28z T CELLS
Overview
Company
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Overview
Modality
CGT
Overview
Target
Non-Hodgkin's Lymphoma
Overview
Indication
Non-Hodgkin's Lymphoma
Overview
Phase
PHASE_1
Overview
Status
RECRUITING
Overview
Content status
Standard Database
Overview
Data Confidence
Data Confidence · Medium
Overview
Development Signal
Development Signal · Watch
Overview
Approval status
Investigational
PK/PD
Species
Mouse
PK/PD
Animal (cat.)
Human, Mouse, In vitro
PK/PD
Experiment
Human T cells engineered to express a chimeric antigen receptor (CAR) recognize and kill tumor cells in a MHC-unrestricted manner and persist in vivo when the CAR includes a CD28 costimulatory domain.
Toxicology
Species
Mouse
Toxicology
Animal (cat.)
Human, Mouse, In vitro
Toxicology
Major finding
A novel generation 1928zT2 CAR T cells induce remission in extramedullary relapse of acute lymphoblastic leukemia.. Anti-CD19 chimeric antigen receptor (CAR) T cells have shown promise in the treatment of B cell acute lymphocytic leukemia (B-ALL). However, its efficacy in B-ALL patients with extramedullary involvement is limited due to poor responses and neurotoxicity. Here, we utilized a third ge…
Toxicology
CRS
grade 2
Clinical
Safety signal
A novel generation 1928zT2 CAR T cells induce remission in extramedullary relapse of acute lymphoblastic leukemia.. Anti-CD19 chimeric antigen receptor (CAR) T cells have shown promise in the treatment of B cell acute lymphocytic leukemia (B-ALL). However, its efficacy in B-ALL patients with extramedullary involvement is limited due to poor responses and neurotoxicity. Here, we utilized a third ge…
Clinical
Program phase
PHASE_1
Preclinical
Animal (cat.)
Mouse, In vitro